XYRATEX LTDAUDITED CONSOLIDATED BALANCE SHEETSNovember 30,2005 2004(US dollars andamounts in thousands)ASSETSCurrent assets:Cash and cash equivalents ....................................... $ 41,240 $ 63,495Accounts receivable, net of allowance for doubtful amounts of $316 and $198 . . 82,449 49,656Inventories ................................................ 71,543 43,014Prepaid expenses ............................................ 2,244 2,594Deferred income taxes ........................................ 6,480 6,774Other current assets .......................................... 3,236 2,855Total current assets ........................................ 207,192 168,388Property, plant and equipment, net ............................... 25,643 14,495Intangible assets, net ......................................... 50,904 7,911Deferred income taxes ........................................ 17,551 14,448Total assets .............................................. $ 301,290 $ 205,242LIABILITIES AND SHAREHOLDERS’ EQUITYCurrent liabilities:Accounts payable ............................................ $ 79,927 $ 47,067Acquisition note payable ...................................... 3,000 2,000Short-term borrowings ........................................ 4,000 4,000Employee compensation and benefits payable ....................... 13,620 10,811Deferred revenue ............................................ 16,434 1,887Income taxes payable ......................................... 421 462Deferred income taxes ........................................ — 536Other accrued liabilities ....................................... 15,506 10,778Total current liabilities ...................................... 132,908 77,541Long-term debt ............................................. 7,000 11,000Total liabilities ............................................ 139,908 88,541Commitments and contingencies (note 14)Shareholders’ equityCommon shares of <strong>Xyratex</strong> Ltd (in thousands), par value $0.01 per share70,000 authorized, 28,437 and 28,043 issued and outstanding ........... 284 280Additional paid-in capital ...................................... 333,886 329,267Accumulated other comprehensive income (loss) ..................... (1,356) 755Accumulated deficit .......................................... (171,432) (213,601)Total shareholders’ equity .................................... 161,382 116,701Total liabilities and shareholders’ equity ......................... $ 301,290 $ 205,242The accompanying notes are an integral part of these consolidated financial statementsF-2
XYRATEX LTDAUDITED CONSOLIDATED STATEMENTS OF OPERATIONSYear Ended November 30,2005 2004 2003(US dollars and amounts in thousandsexcept per share amounts)Revenues .................................... $679,609 $ 459,014 $333,769Cost of revenues—non cash equity compensation .......... — 7,827 690Cost of revenues—other .......................... 535,315 535,315 356,558 364,385 260,020 260,710Gross profit .................................. 144,294 94,629 73,059Operating expenses:Research and development—development arrangement .... — (6,000) —Research and development—non cash equity compensation . — 23,959 2,428Research and development—other .................. 54,327 54,327 37,429 55,388 29,797 32,225Selling, general and administrative—non cash equitycompensation .............................. 828 136,363 54,143Selling, general and administrative—other ............. 38,014 38,842 28,005 164,368 22,426 76,569Amortization of intangible assets ................... 3,218 1,169 —In process research and development ................ 3,230 852 —Other costs ................................. — 2,388 11,625Total operating expenses ....................... 99,617 224,165 120,419Operating income (loss) .......................... 44,677 (129,536) (47,360)Interest income (expense), net ...................... 1,176 1,052 (209)Income (loss) from continuing operations before income taxes . 45,853 (128,484) (47,569)Provision (benefit) for income taxes ................... 3,964 (6,239) (11,754)Net income (loss) from continuing operations ............ 41,889 (122,245) (35,815)Income (loss) from discontinued operations (net of taxes) . . . 280 (12,924) (20,194)Loss from sale of discontinued operations (net of taxes ofzero) .................................... — — (185)Net income (loss) .............................. $42,169 $(135,169) $(56,194)Net earnings (loss) per share—basic:Net income (loss) from continuing operations ........... $ 1.48 $ (6.72) $ (9.60)Income (loss) from discontinued operations, net of incometax ..................................... 0.01 (0.71) (5.41)Loss from sale of discontinued operations, net of income tax — — (0.05)Net earnings (loss) per share ...................... $ 1.49 $ (7.43) $ (15.07)Net earnings (loss) per share—diluted:Net income (loss) from continuing operations ........... $ 1.44 $ (6.72) $ (9.60)Income (loss) from discontinued operations, net of incometax ..................................... 0.01 (0.71) (5.41)Loss from sale of discontinued operations, net of income tax — — (0.05)Net earnings (loss) per share ...................... $ 1.45 $ (7.43) $ (15.07)Weighted average common shares, class B preferred ordinaryshares and class B ordinary shares (in thousands), used incomputing net earnings (loss) per share (1) :Basic ..................................... 28,329 18,195 3,730Diluted .................................... 29,031 18,195 3,730(1) In 2005 includes only common shares.The accompanying notes are an integral part of these consolidated financial statementsF-3
- Page 3:
XYRATEX LTDANNUAL REPORT FOR THE YE
- Page 6 and 7:
INTRODUCTIONWe are incorporated und
- Page 8 and 9:
Year Ended November 30,2005 2004 20
- Page 10 and 11:
The computations for the weighted a
- Page 12 and 13:
The markets in which we operate are
- Page 14 and 15:
technological capabilities. This co
- Page 16 and 17:
may cease production of components,
- Page 18 and 19:
• potentially adverse tax consequ
- Page 20 and 21:
We could incur substantial costs, i
- Page 22 and 23:
influence by voting at a meeting of
- Page 24 and 25:
Xyratex Ltd to the former sharehold
- Page 26 and 27:
In addition to the rapid growth of
- Page 28 and 29:
RAID controller technology is proje
- Page 30 and 31:
Our Competitive StrengthsDisk drive
- Page 32 and 33:
the storage subsystem and disk driv
- Page 34 and 35:
Our storage subsystems are internal
- Page 36 and 37:
systems are capable of testing a fu
- Page 38 and 39:
Research and DevelopmentWe have ove
- Page 40 and 41:
• sets forth procedures for the p
- Page 42 and 43: Item 4C: Organization StructureXyra
- Page 44 and 45: ecame the parent company of our bus
- Page 46 and 47: Foreign Exchange Rate FluctuationsT
- Page 48 and 49: we recorded in the year ended Novem
- Page 50 and 51: Fiscal Year Ended November 30, 2005
- Page 52 and 53: Research and Development—otherThe
- Page 54 and 55: Fiscal Year Ended November 30, 2004
- Page 56 and 57: Selling, General and Administrative
- Page 58 and 59: Quarterly Results of OperationsThe
- Page 60 and 61: sales growth. The increase in defer
- Page 62 and 63: choose to make or alliances we have
- Page 64 and 65: compete. Identifiable intangible as
- Page 66 and 67: ITEM 6: DIRECTORS, SENIOR MANAGEMEN
- Page 68 and 69: Ernest Sampias has served as a dire
- Page 70 and 71: Audit CommitteeOur Audit Committee
- Page 72 and 73: Employee Benefit/Share Option Plans
- Page 74 and 75: The maximum amount that any partici
- Page 76 and 77: Restricted StockRestricted stock aw
- Page 78 and 79: the options, warrants or rights, bu
- Page 80 and 81: Quarterly high and low market price
- Page 82 and 83: whose functional currency is not th
- Page 84 and 85: on the Nasdaq National Market and,
- Page 86 and 87: Interest RatesWe had cash and cash
- Page 88 and 89: aggregate in any fiscal year and th
- Page 90 and 91: (This page has been left blank inte
- Page 94 and 95: F-4XYRATEX LTDAUDITED CONSOLIDATED
- Page 96 and 97: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 98 and 99: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 100 and 101: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 102 and 103: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 104 and 105: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 106 and 107: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 108 and 109: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 110 and 111: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 112 and 113: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 114 and 115: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 116 and 117: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 118 and 119: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 120 and 121: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 122 and 123: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 124 and 125: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 126 and 127: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 128 and 129: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 130: (This page has been left blank inte